Lumos Diagnostics Holdings Limited
Lumos Diagnostics Holdings Limited Fundamental Analysis
Lumos Diagnostics Holdings Limited (LDX.AX) shows moderate financial fundamentals with a PE ratio of -11.96, profit margin of -75.84%, and ROE of -1.64%. The company generates $0.0B in annual revenue with moderate year-over-year growth of 5.66%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -211.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze LDX.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakLDX.AX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentLDX.AX trades at attractive valuation levels.
Growth Score
ExcellentLDX.AX delivers strong and consistent growth momentum.
Financial Health Score
WeakLDX.AX carries high financial risk with limited liquidity.
Profitability Score
WeakLDX.AX struggles to sustain strong margins.
Key Financial Metrics
Is LDX.AX Expensive or Cheap?
P/E Ratio
LDX.AX trades at -11.96 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, LDX.AX's PEG of 1.00 indicates fair valuation.
Price to Book
The market values Lumos Diagnostics Holdings Limited at 21.35 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -11.48 times EBITDA. This is generally considered low.
How Well Does LDX.AX Make Money?
Net Profit Margin
For every $100 in sales, Lumos Diagnostics Holdings Limited keeps $-75.84 as profit after all expenses.
Operating Margin
Core operations generate -81.50 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.64 in profit for every $100 of shareholder equity.
ROA
Lumos Diagnostics Holdings Limited generates $-44.27 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Lumos Diagnostics Holdings Limited generates limited operating cash flow of $-2.31M, signaling weaker underlying cash strength.
Free Cash Flow
Lumos Diagnostics Holdings Limited generates weak or negative free cash flow of $-2.55M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.00 in free cash annually.
FCF Yield
LDX.AX converts -2.14% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-11.96
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.003
vs 25 benchmark
P/B Ratio
Price to book value ratio
21.35
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.36
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.26
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.73
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-1.64
vs 25 benchmark
ROA
Return on assets percentage
-0.44
vs 25 benchmark
ROCE
Return on capital employed
-0.95
vs 25 benchmark
How LDX.AX Stacks Against Its Sector Peers
| Metric | LDX.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -11.96 | 28.45 | Better (Cheaper) |
| ROE | -164.12% | 763.00% | Weak |
| Net Margin | -75.84% | -45265.00% (disorted) | Weak |
| Debt/Equity | 2.26 | 0.34 | Weak (High Leverage) |
| Current Ratio | 0.73 | 2795.60 | Weak Liquidity |
| ROA | -44.27% | -16588.00% (disorted) | Weak |
LDX.AX outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Lumos Diagnostics Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-91.50%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
93.61%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
101.07%
Industry Style: Defensive, Growth, Innovation
High Growth